Trxade Group (MEDS)
(Delayed Data from NSDQ)
$7.90 USD
+0.21 (2.73%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $7.94 +0.04 (0.51%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
TRxADE HEALTH, Inc. [MEDS]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Discontinuing coverage due to termination of services
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Optimized Entry and Exit Levels for MEDS 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
We are removing are rating and price target due to merger related activities
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating and 12-month price target of $0.45 per share.
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating but reducing our 12-month price target to $0.45 per share.
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating but reducing our 12-month price target to $1.75 per share from $3.00 per share due to reductions in our 2023
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating but reducing our 12-month price target to $3.00 per share from $3.75 per share due to a reduced 2023 sales per share
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating but reducing our 12-month price target to $3.75 per share from $6.25 per share
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating but reducing our 12-month price target to $6.25 per share from $7.00 per share based on our 2023 revenue per share forecast.
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating and 12-month price target of $7.00 per share
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating but reducing our 12-month price target to $7.00 per share
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating but reducing our 12-month price target to $7.25 from $9.50 per share due to a reduced 2022 EPS forecast
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating and 12-month price target of $9.50 per share.
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating but decreasing our 12-month price target to $9.50 per share from $10.50 per share
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Maintaining Speculative Buy rating and increasing our 12-month price target to $10.50 per share from $9.50 per share
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: TRxADE HEALTH, Inc.
Industry: Internet - Commerce
Initiating with a Speculative Buy rating and 12-month price target of $9.50 per share based on our 2021 EPS forecast.
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
|